The FTC just went after 'bundling' in Amgen's $28B deal. Will it put a chill on future M&A?
The FTC’s surprising and potentially risky attempt to block Amgen’s proposed $28 billion buyout of Horizon Therapeutics has raised concerns about federal oversight of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
